Risperdal Lawsuit Alleges Louisiana Boy Developed Gynecomastia Due to Risperdal, Risperdal Consta and Invega Side Effects, Bernstein Liebhard LLP Reports

Share Article

The Firm is currently representing numerous men and boys in Risperdal lawsuits that also allege the drug caused gynecomastia, a condition marked by the excessive breast growth in male patients.

Free Case Review
Our Firm is representing a number of individuals in Risperdal gynecomastia claims, and we continue to receive inquiries from others who allegedly experienced this painful and embarrassing complication due to its use.

Risperdal lawsuits (http://www.risperdallawsuit2014.com/) that allege the medication can cause gynecomastia, or male breast development, when used to treat men or boys continue to mount in courts throughout the country, Bernstein Liebhard LLP reports. Most recently, one such claim was filed in U.S. District Court, Eastern District of Louisiana, by a woman who alleges her son developed the condition due to treatment with Risperdal, as well as a long-acting, injectable version of the drug called Risperdal Consta, and Invega, another antipsychotic which is an active metabolite of Risperdal. According to the December 17th filing, the child was treated with the various medications between 2001 and 2008, and developed lactating breasts during that time. The Risperdal lawsuit filed by his mother seeks compensation for the physical and emotional damages he allegedly sustained as a result of this complication. (Case 2:14-cv-02873)

“Our Firm is representing a number of individuals in Risperdal gynecomastia claims, and we continue to receive inquiries from others who allegedly experienced this painful and embarrassing complication due to its use. As such, we are closely monitoring any litigation involving this medication,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal or Invega.

Risperdal Gynecomastia Litigation
According to court documents, more than 1,100 Risperdal, Risperdal Consta and Invega lawsuits are now pending in a mass tort litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, where Bernstein Liebhard LLP is actively filing claims. All of these lawsuits were filed on behalf of individuals who allegedly suffered serious side effects related to their use, including gynecomastia, a condition marked by the excessive growth of breast tissue in boys and men. Among other things, the complaints accuse Johnson & Johnson and Janssen of improperly marketing the medications for off-label pediatric uses, and of failing to warn that these drugs can cause the body to produce excess amounts of prolactin, a hormone tied to female breast growth and lactation. (In Re: Risperdal Litigation, Case Number 100300296).

In November 2013, Johnson & Johnson and Janssen agreed to pay $2.2 billion to resolve criminal and civil charges levied by the U.S. Department of Justice regarding the marketing of several medications, including Risperdal and Invega. Among other things, the companies were accused of improperly promoting the antipsychotic drugs for unapproved uses, and of paying kickbacks to physicians who prescribed Risperdal. According to the Department of Justice, the settlement ranked among the largest involving healthcare fraud in U.S. history. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia due to treatment with Risperdal, Risperdal Consta or Invega may be entitled to compensation for the physical, financial and emotional damages related to their injuries. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuit2014.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website